glucose-na-k baxter 50 mg/ml infusionsvätska, lösning
maintelyte solution for infusion
baxter holding b.v. kobaltweg 49, 3542ce utrecht, netherlands - glucose anhydrous, sodium chloride, sodium acetate, trihydrate, potassium chloride, magnesium chloride, hexahydrate - solution for infusion - glucose anhydrous 50 g sodium chloride 1 g sodium acetate trihydrate 3.13 g potassium chloride 1.5 g magnesium chloride hexahydrate 0.30 g - blood substitutes and perfusion solutions
4farmers 1080 impregnated oats (fox control)
4 farmers australia pty ltd - sodium fluoroacetate - bait - sodium fluoroacetate mineral-fluorine active 3.0 mg - vertebrate poison
benzalkonium chloride- hot spot skin remedy gel
sergeant's pet care products, inc - benzalkonium chloride (unii: f5um2km3w7) (benzalkonium - unii:7n6jud5x6y) - benzalkonium chloride 0.13 g in 118 ml - fast relief. effective. soothing. non-stinging. alcohol-free. petarmor for dogs hot spot skin remedy kills topical bacteria, fungus and viruses associated with hot spots. remedy for superficial cuts, scrapes, and abrasions. other hot spot signs: biting and skin flaking.
actilyse powder lyophilized for solution for infusion with solvent
boehringer ingelheim pharma gmbh & co. kg - alteplase - powder lyophilized for solution for infusion with solvent - 50mg
bupropion hydrochloride- bupropion hydrochloride tablet, film coated, extended release
mylan pharmaceuticals inc. - bupropion hydrochloride (unii: zg7e5poy8o) (bupropion - unii:01zg3tpx31) - bupropion hydrochloride extended-release tablets (xl) are indicated for the treatment of major depressive disorder (mdd), as defined by the diagnostic and statistical manual (dsm). the efficacy of the immediate-release formulation of bupropion was established in two 4-week controlled inpatient trials and one 6-week controlled outpatient trial of adult patients with mdd. the efficacy of the sustained-release formulation of bupropion in the maintenance treatment of mdd was established in a long-term (up to 44 weeks), placebo-controlled trial in patients who had responded to bupropion in an 8-week study of acute treatment [see clinical studies (14.1)] . bupropion hydrochloride extended-release tablets (xl) are indicated for the prevention of seasonal major depressive episodes in patients with a diagnosis of seasonal affective disorder (sad). the efficacy of bupropion hydrochloride extended-release tablets in the prevention of seasonal major depressive episodes was established in 3 placebo-controlled trials in ad
signature femoral head (ceramic) - ceramic femoral head prosthesis
signature orthopaedics pty ltd - 38156 - ceramic femoral head prosthesis - the signature femoral head (ceramic) mates with a femoral stem via taper connection, and replaces the articular surface of the patient's natural femoral head as part of a total hip joint replacement. the device is manufactured from biolox delta ceramic. the signature femoral head (ceramic) is intended to replace the articular surface of the patient's femoral head as part of a total hip joint replacement, where bone stock is sufficient to support the implant. the device is indicated for use in skeletally mature individuals undergoing primary surgery for hip replacement due to osteoarthritis, avascular necrosis, rheumatoid arthritis, congenital hip dysplasia, traumatic injury of the proximal femur, or failed previous hip surgery.
signature femoral head (cocr) - metallic femoral head prosthesis
signature orthopaedics pty ltd - 33175 - metallic femoral head prosthesis - the signature femoral head (cocr) mates with a femoral stem via taper connection, and replaces the articular surface of the patient's natural femoral head as part of a total hip joint replacement. the device is manufactured from cocr alloy. the signature femoral head (cocr) is intended to replace the articular surface of the patient's femoral head as part of a total hip joint replacement, where bone stock is sufficient to support the implant. the device is indicated for use in skeletally mature individuals undergoing primary surgery for hip replacement due to osteoarthritis, avascular necrosis, rheumatoid arthritis, congenital hip dysplasia, traumatic injury of the proximal femur, or failed previous hip surgery.
brinavess 20 mgml
tzamal bio-pharma ltd - vernakalant hydrochloride - concentrate for solution for infusion - vernakalant hydrochloride 20 mg/ml - vernakalant - vernakalant - rapid conversion of recent onset atrial fibrillation to sinus rhythm in adults who are hemodynamically stable.- for non-surgery patients: atrial fibrillation ≤ 7 days duration- for post-cardiac surgery patients: atrial fibrillation ≤ 3 days duration
magna omega 3- omega-3 fatty acids capsule, gelatin coated
magna pharmaceuticals, inc. - fish oil (unii: xgf7l72m0f) (fish oil - unii:xgf7l72m0f) - supports cardiovascular and brain health